Cabello (encanecimiento)

Acetyl-L-Carnitine (ALCAR) has been investigated in Parkinson's disease for its mitochondrial-protective and antioxidant properties. Preclinical studies show it protects dopaminergic neurons against neurotoxin-induced damage. Small clinical studies suggest potential benefit in neuroprotection and symptom management, though large-scale RCTs are lacking.

A 2022 peer-reviewed PMC study (University of Tsukuba) found that amber extract protects human dopaminergic neuronal cells against 6-hydroxydopamine-induced apoptosis in a PD cell model, acting via ROS reduction and autophagy promotion. Evidence is preclinical only.

The ScienceDirect pharmacological overview of anemarrhena lists Parkinson's disease as a therapeutic target alongside Alzheimer's disease. Sarsasapogenin and mangiferin show neuroprotective activity in relevant preclinical models, including protection against neurotoxin-induced neurodegeneration.

Evidence for Parkinson's disease is currently preclinical and mechanistic: astaxanthin has been shown in cell-based and animal studies to modulate oxidative stress, neuroinflammation, and apoptosis in dopaminergic neurons. A 2025 review (Frontiers in Aging Neuroscience) confirms potential neuroprotective effects in PD models, but no human RCTs in PD patients have been completed.

Baicalein, a bioactive flavone from Scutellaria baicalensis (Baikal skullcap), has demonstrated consistent neuroprotective effects in animal models of Parkinson's disease. A 2020 systematic review and meta-analysis of 20 preclinical studies confirmed significant improvements in motor and dopaminergic outcomes. Clinical translation is underway but human trial data remain limited.

Piperine inhibits MAO-B (the enzyme that degrades dopamine), crosses the blood-brain barrier, and protects dopaminergic neurons in multiple animal and cell models of Parkinson's disease. In rotenone-induced neurotoxicity models, piperine restored mitochondrial function in neuronal cells. Evidence is entirely preclinical.

Broad beans (Vicia faba) contain natural L-DOPA and have documented clinical evidence of producing motor improvement in Parkinson's disease patients. Small clinical studies show consumption of 250 g cooked broad beans raises plasma L-DOPA to therapeutic levels, improving motor performance in PD patients.

At least six large prospective epidemiological studies have established an inverse association between caffeine consumption and risk of developing Parkinson's disease. The mechanism involves A2A adenosine receptor antagonism, which may confer neuroprotection against dopaminergic neurodegeneration. Clinical evidence for slowing disease progression is emerging but not yet conclusive.

BCP has protected dopaminergic neurons from MPTP-induced death in multiple mouse models via antioxidant (NQO1, Nrf2), anti-inflammatory, and CB2-mediated neuroprotective mechanisms. Multiple independent preclinical studies support this.

Catalase activity is consistently reduced in the blood of Parkinson's disease (PD) patients compared to controls, as confirmed by multiple meta-analyses. The substantia nigra in PD is under intense oxidative stress, and H₂O₂—the direct substrate of catalase—is generated in excess through dopamine metabolism. Experimental catalase mimetics show neuroprotective properties in animal models.

EGCG has neuroprotective effects relevant to Parkinson's disease through inhibition of dopaminergic neuron apoptosis, mitochondrial protection, and reduction of neuroinflammation. Epidemiological evidence links tea consumption to reduced PD risk, and EGCG's effects on PD models have been examined in clinical trials.

Chrysin demonstrates neuroprotective effects in multiple Parkinson's disease (PD) models, protecting dopaminergic neurons in the substantia nigra, inhibiting monoamine oxidase B (MAO-B), and restoring striatal dopamine. It reduces motor and cognitive deficits in 6-OHDA and MPTP animal models. All evidence is preclinical.

Citicoline (CDP-choline) has been studied in Parkinson's disease for its ability to increase dopamine synthesis and inhibit dopamine reuptake, supporting nigrostriatal function. A meta-analysis reviewed seven clinical studies, though heterogeneity in outcome measures limited conclusions. It is recognized by the American Parkinson Disease Association (APDA) as having some evidence for PD.

CoQ10 has been extensively studied in Parkinson's disease based on evidence of mitochondrial Complex I deficiency in PD patients. Phase II trials showed dose-dependent slowing of functional decline; however, a large Phase III RCT (QE3) failed to confirm disease-modifying benefit. Meta-analyses show it is safe but does not significantly improve motor UPDRS scores versus placebo.

Cowage seed (Mucuna pruriens) contains 4–6% natural L-DOPA, the gold-standard pharmacotherapy for Parkinson's disease. A 2024 systematic review of 5 clinical trials (n=108) found consistent improvements in PD motor symptoms and therapy complications with shorter off-periods and less dyskinesia versus standard levodopa. Ayurvedic traditional use for parkinsonism predates modern medicine.

Creatine was investigated in Parkinson's disease in multiple trials based on its mitochondrial-supportive and neuroprotective properties. A large NINDS-sponsored Phase III NET-PD trial of creatine monohydrate (10 g/day) in early PD was stopped for futility in 2013. Prior Phase II results had been mixed but suggestive, and the APDA notes clinical trials showed no benefit.

Curcumin, the principal bioactive polyphenol in turmeric, has been studied in Parkinson's disease for its ability to inhibit α-synuclein aggregation, reduce neuroinflammation, and modulate oxidative stress. A 2025 systematic review identified two RCTs and one cohort study in PD patients. Preclinical evidence is strong, but clinical translation is hampered by poor bioavailability.

DHA, the primary omega-3 fatty acid in brain tissue, has been studied in Parkinson's disease for its neuroprotective and anti-neuroinflammatory properties. Small clinical studies suggest omega-3 supplementation (including DHA) may modestly improve UPDRS scores in PD patients. Epidemiological data link higher fish oil/omega-3 intake with reduced PD risk.

EGCG, the major polyphenol in green tea, has demonstrated neuroprotective effects in multiple experimental PD models through inhibition of α-synuclein aggregation, MAO-B inhibition, antioxidant activity, and iron chelation. Epidemiological studies link regular green tea consumption to reduced PD risk. Robust clinical trials specific to EGCG in PD are limited.

Multiple preclinical studies demonstrate eucommia extracts protect dopaminergic neurons against MPTP/MPP+ toxicity (standard Parkinson's models), with anti-neuroinflammatory effects via p38/JNK-Fosl2 pathway regulation. A 2025 zebrafish study identified specific anti-PD active constituents in eucommia leaves acting via 4E-BP1 upregulation. No human clinical trials exist.

Fava beans (Vicia faba) naturally contain L-DOPA (0.5% fresh, 0.07% dried), the gold standard pharmacological treatment for Parkinson's disease. Clinical case reports and small studies show significant motor improvement in PD patients consuming cooked fava beans. L-DOPA was first isolated from fava beans by Guggenheim in 1913.

Ferulic acid has demonstrated neuroprotection in multiple Parkinson's disease animal models by reducing dopaminergic neuron loss, attenuating neuroinflammation, and activating the Nrf2/ERK1/2-dependent antioxidant pathway. It reinstates mitochondrial dynamics through PGC1α modulation in 6-OHDA-lesioned rats and protects against MPTP/MPP+-induced oxidative stress. Human clinical evidence is currently limited to the preclinical-to-translational stage.

Fisetin protects dopaminergic neurons against MPTP-induced degeneration in mouse PD models, modulates gut microbiota through the gut-brain axis, restores proteasome activity, and reduces alpha-synuclein pathology. One human case-control study showed dietary fisetin-containing food improved PD motor symptoms.

Geniposide and genipin from Gardenia jasminoides have demonstrated neuroprotective effects against dopaminergic neuron loss in MPTP-induced Parkinson's disease mouse models, mediated by anti-inflammatory and anti-apoptotic mechanisms. Crocin reversed depression-like behavior in a PD mouse model via VTA-mPFC dopaminergic pathway modulation. Evidence is entirely preclinical.

GE and gastrodin have been studied in 6-OHDA Parkinson's disease models, showing neuroprotective effects and reduction of L-DOPA-induced dyskinesia. Gastrodin is listed among compounds used clinically in China for Parkinson's syndrome. Multiple preclinical studies support dopaminergic neuroprotection.

Gastrodin, the primary bioactive glycoside of Gastrodia elata (a Chinese medicinal herb used in traditional medicine for neurological conditions), has shown neuroprotective effects in multiple PD animal models. It protects dopaminergic neurons, reduces neuroinflammation, and maintains dopamine homeostasis. Research is primarily preclinical with growing mechanistic clinical interest.

Ginkgo biloba extract (EGb761) has been studied in both animal models and clinical settings for Parkinson's disease. Animal studies consistently show neuroprotection of dopaminergic neurons via MAO-B inhibition and antioxidant activity. A clinical RCT assessed its efficacy in drug-induced parkinsonism. A 2013 systematic review of 10 controlled animal studies confirmed neuroprotective effects.

GPC has limited but documented human evidence for improving cognitive and neuropsychological symptoms in Parkinson's disease patients with dementia, used adjunctively to standard dopaminergic therapy. The plausible mechanism involves cholinergic augmentation in a disease where both dopaminergic and cholinergic systems are impaired. Evidence quality is low and no current clinical guidelines recommend it for PD.

Green tea and its polyphenols (primarily EGCG) have been associated with reduced Parkinson's disease risk in multiple epidemiological studies. Meta-analyses of population studies show regular tea consumption reduces PD risk. Mechanistically, green tea catechins protect dopaminergic neurons through antioxidant, anti-inflammatory, and α-synuclein inhibiting effects.

Hericium erinaceus (lion's mane mushroom) contains hericenones and erinacines that stimulate nerve growth factor (NGF) synthesis, with established neuroprotective properties relevant to Parkinson's disease. Preclinical studies show it attenuates dopaminergic neurodegeneration and reduces α-synuclein pathology. Clinical evidence is preliminary.

Hesperidin has been studied extensively in preclinical Parkinson's disease models. It protects dopaminergic neurons in the substantia nigra, modulates serotonergic and kappa-opioid receptors, enhances dopamine and its metabolites, and reduces oxidative stress and neuroinflammation. Human clinical data are lacking; evidence is currently preclinical.

A rodent study using the 6-OHDA unilateral striatal injection model of Parkinson's disease found that chronic oral treatment with HMR/lignan slowed the progression of nigrostriatal dopaminergic terminal degeneration and improved motor performance. Anti-inflammatory and antioxidant mechanisms are implicated.

In a 6-OHDA rat model of Parkinson's disease, chronic HMR treatment reduced striatal neuroinflammation, decreased microglial and astrocyte activation markers, and attenuated motor deficits, though it did not significantly increase dopaminergic neuronal survival. HMR and its metabolites have been shown to reach brain tissue after oral dosing. Evidence is entirely preclinical.

Multiple preclinical studies demonstrate that gypenosides protect dopaminergic neurons in rodent models of Parkinson's disease (6-OHDA and MPTP models). Additionally, gypenosides attenuate L-DOPA-induced dyskinesia in animal models. No human clinical trial has been conducted.

A pilot human study found that adding 1.5 g/day L-carnosine to standard L-DOPA therapy produced ~36% improvement in Parkinson's clinical symptoms versus ~16% with medication alone. Preclinical evidence shows carnosine reduces oxidative stress, inhibits alpha-synuclein aggregation, and is neuroprotective in PD models. Larger trials are absent.

Glutathione (GSH), the brain's primary antioxidant, is significantly depleted in the substantia nigra of Parkinson's disease patients. Intravenous glutathione administration in small clinical trials has shown symptom improvement in PD. Direct supplementation and precursor strategies (NAC) have been studied, though oral bioavailability of L-glutathione to the brain is limited.

L-methionine activates methionine sulfoxide reductase A/B and supports glutathione biosynthesis, both of which counteract the oxidative stress and mitochondrial dysfunction central to Parkinson's pathology. An in vitro study using a 6-OHDA dopaminergic neuron model demonstrated that L-methionine protected against oxidative stress and mitochondrial damage. However, L-methionine can competitively reduce levodopa absorption across the blood-brain barrier, an established clinical concern.

Phenylalanine metabolism is measurably altered in Parkinson's disease patients, with reduced tyrosine-to-phenylalanine ratios observed in serum. Mendelian randomization and metabolomic studies have examined causal and associative relationships. L-phenylalanine's role as a dopamine precursor (via tyrosine) is particularly relevant given the dopaminergic deficit in PD.

Altered levels of L-serine and D-serine have been documented in postmortem brain tissue and cerebrospinal fluid of Parkinson's disease (PD) patients, and preclinical studies demonstrate neuroprotective effects of L-serine in PD models. L-serine treatment has been shown to offer beneficial effects for dopaminergic neuron survival in preclinical settings, though no human clinical trial targeting PD specifically has been completed.

Lion's Mane (Hericium erinaceus) contains erinacines and hericenones that stimulate NGF production and have demonstrated neuroprotective effects in preclinical Parkinson's disease models. Erinacine A increases striatal dopamine levels in animal studies. Preliminary clinical evidence from neurological trial settings supports safety and potential neuroprotective benefit.

Preclinical models and pilot human trials support lithium as a potential neuroprotective agent in Parkinson's disease (PD), with evidence of reduced neuroinflammation, α-synuclein pathology, and a biomarker of axonal injury. A 2023 pilot clinical trial and ongoing phase 1b trials are investigating low-dose lithium, including the orotate formulation as a comparator.

Luteolin is neuroprotective in multiple Parkinson's disease cell and animal models, protecting dopaminergic neurons from MPP+, 6-OHDA, and manganese neurotoxicity via Nrf2 activation, mitochondrial protection, and neuroinflammation suppression. Evidence is preclinical; clinical data involve the PEA+luteolin combination.

Emerging clinical interest in MCT for Parkinson's disease (PD) is based on evidence that cerebral glucose hypometabolism occurs in PD as in Alzheimer's, and that ketone bodies may support dopaminergic neuron function. An ongoing open-label trial (NCT04322461) is evaluating 50 g/day MCT with supervised exercise in 20 AD or PD patients. Decanoic acid has shown preclinical promise in reducing oxidative stress relevant to neurodegeneration.

Melatonin, the pineal hormone with potent antioxidant and neuroprotective properties, is often studied in Parkinson's disease. Sleep disturbances are among the most common non-motor symptoms of PD, and melatonin has evidence for improving sleep in PD patients. Additionally, preclinical studies demonstrate it protects dopaminergic neurons from oxidative damage.

N-Acetyl Cysteine (NAC) raises brain glutathione levels and has been studied in Parkinson's disease as a neuroprotective antioxidant. A pilot clinical trial (Thomas Jefferson University, 2019) showed NAC increased dopamine transporter binding on DaTSCAN and significantly improved UPDRS scores in PD patients. Larger trials are needed.

Naringenin (naringin's aglycone) exerts neuroprotective effects in rotenone and other Parkinson's disease animal models by increasing DJ-1 and chaperone-associated E3 ligase expression, protecting dopaminergic neurons in the substantia nigra. Naringin may aid dopaminergic neuron recovery after injury. Evidence is entirely preclinical.

Two phase I randomized controlled trials have directly tested NR in Parkinson's disease patients. The NADPARK study (n=30, 1,000 mg/day for 30 days) showed NR significantly increased cerebral NAD+ levels and was associated with mild clinical improvement. A separate RCT at 3,000 mg/day for 4 weeks also showed significant clinical symptom improvement. A larger 400-person 1-year trial (NOPARK) is ongoing.

Omega-3 fatty acids (EPA and DHA) have been investigated in Parkinson's disease for their anti-neuroinflammatory and neuroprotective properties. Small clinical studies report improvement in UPDRS scores. A real-world PD patient survey found omega-3/fish oil among the most commonly used and most symptom-improving supplements in PD.

Tenuigenin, a major active component of P. tenuifolia, protects dopaminergic neurons from MPTP-induced damage in a mouse Parkinson's disease model by suppressing NLRP3 inflammasome activation in microglia. Other PT compounds protect against 6-OHDA-induced injury in dopaminergic cell lines.

Multiple peer-reviewed preclinical studies document that Polygala root constituents (tenuigenin, Polygalae radix extract) protect dopaminergic neurons from toxin-induced injury in validated Parkinson's disease models, suppress NLRP3 inflammasome activation, and improve motor impairment. Evidence is preclinical, not clinical.

In preclinical models, PQQ confers neuroprotection in rotenone- and 6-OHDA-induced Parkinson's disease models by preserving mitochondrial membrane potential, scavenging ROS, and protecting dopaminergic neurons. No human RCT in Parkinson's patients has been completed; evidence is preclinical but mechanistically well-characterized.

Resveratrol, a polyphenol from grapes and red wine, has demonstrated neuroprotective effects in Parkinson's disease models by activating SIRT1, reducing oxidative stress, inhibiting neuroinflammation, and protecting dopaminergic neurons. Preclinical studies show it inhibits LPS-induced neuroinflammation and protects DA neurons in 6-OHDA rodent PD models. Clinical evidence is still early.

Multiple epidemiological studies report an inverse association between coffee consumption and Parkinson's disease (PD) risk, with an optimal protective dose around 3 cups per day. Robusta coffee's high caffeine and chlorogenic acid content underpin these neuroprotective associations. Caffeine blocks adenosine A2A receptors in the basal ganglia, a validated target in PD pathophysiology.

Rosmarinic acid has demonstrated neuroprotective effects in multiple preclinical Parkinson's disease models (MPTP, rotenone, 6-OHDA), protecting dopaminergic neurons via antioxidant, anti-neuroinflammatory, and mitochondrial-protective mechanisms. RA reduces α-synuclein accumulation and HMGB1/TLR4/NF-κB neuroinflammatory signaling in PD models. No human clinical trials for RA in PD have been published.

Rutin shows neuroprotective effects in MPTP-induced Parkinson's disease animal models by preserving dopaminergic neurons, reducing neuroinflammation, and improving motor and memory deficits. Mechanisms include downregulation of PD-linked proapoptotic genes and restoration of mitochondrial function.

SAMe levels are significantly depleted in levodopa-treated Parkinson's disease (PD) patients, as levodopa metabolism via COMT consumes SAMe and elevates homocysteine. An open-label clinical trial in 13 depressed PD patients found that SAMe at doses of 800–3600 mg/day for 10 weeks produced at least 50% improvement on the Hamilton Depression Scale in 10 of 11 completers. Preclinical data in 6-OHDA rat models show SAMe reduces dopaminergic neuronal loss and improves motor coordination. The evidence is scientifically grounded but limited to small, uncontrolled studies.

Schisandrin B shows neuroprotective effects in the 6-OHDA-induced Parkinson's disease rodent model by inhibiting miR-34a-mediated negative modulation of the Nrf2 pathway. Schisandra chinensis lignans are identified in comprehensive reviews as having potential to combat Parkinson's disease via oxidative stress reduction and neuroinflammation modulation.

Silymarin demonstrates neuroprotection in MPTP mouse models of Parkinson's disease, preserving dopaminergic neurons and striatal dopamine levels. Proposed mechanisms include antioxidant, anti-inflammatory, and anti-apoptotic activity in the substantia nigra. Human clinical trial data for Parkinson's disease specifically is not yet established; evidence is currently preclinical.

SPMs reduce dopaminergic neuron loss and neuroinflammation in preclinical Parkinson's disease models. Neuroinflammation and microglial activation are established PD pathomechanisms that SPMs target. Reduced SPM biosynthesis capacity has been associated with PD-relevant neurological deterioration.

Sulforaphane is neuroprotective against dopaminergic neuron loss in Parkinson's disease models via Nrf2 activation, CBS-H2S axis modulation, mitophagy induction, and neuroinflammation suppression. Reviewed as a potential therapeutic in multiple peer-reviewed analyses; human clinical trials are ongoing.

Taurine demonstrates neuroprotective effects in animal models of Parkinson's disease, inhibiting microglial NADPH oxidase activation, protecting dopaminergic neurons, and improving motor and cognitive outcomes. The evidence base is entirely preclinical; no human PD-specific RCTs have been conducted.

Preclinical and mechanistic reviews identify pterostilbene as a neuroprotective agent in Parkinson's disease models, acting by restoring mitochondrial retrograde signaling, inhibiting NF-κB, and protecting dopaminergic neurons. No human clinical trials in PD have been conducted.

UA's anti-inflammatory, antioxidant, and mitophagy-enhancing properties are mechanistically highly relevant to Parkinson's disease (PD). Preclinical studies show UA preserves dopaminergic neurons, inhibits α-synuclein aggregation, and suppresses neuroinflammation. The Buck Institute is conducting dedicated UA PD research; however, PD-specific human trial data are limited to early-phase work.

Velvet bean seeds contain 4–6% L-DOPA by weight, making them a natural levodopa source for Parkinson's disease. Multiple small clinical trials show comparable or superior motor improvement versus standard levodopa/carbidopa, with faster onset and fewer dyskinesias. A 2025 systematic review of five clinical trials (108 participants) confirmed these findings. The seed likely exerts additional benefit beyond L-DOPA content alone, through antioxidant and anti-neuroinflammatory mechanisms.

An open-label trial (2003) found that high-dose riboflavin supplementation combined with dietary red meat elimination improved motor function in Parkinson's disease patients. Riboflavin is a cofactor for pyridoxine phosphate oxidase, required to activate vitamin B6—itself linked to PD risk reduction. A 2024 gut microbiota meta-analysis identified riboflavin and biotin depletion as consistent features of PD gut microbiome.

Vitamin D deficiency is significantly more prevalent in Parkinson's disease patients than in healthy controls, with a meta-analysis of 63 studies confirming lower vitamin D levels and higher odds of deficiency in PD. Cohort data suggest sufficient vitamin D may reduce PD risk. Supplementation studies show modest, non-significant improvements in motor outcomes.

Vitamin D3 (cholecalciferol) is the most bioavailable form of vitamin D, with consistent evidence of deficiency in Parkinson's disease patients. Observational studies link higher serum 25(OH)D3 levels with lower PD incidence. Small RCTs of D3 supplementation have been conducted in PD with modest motor improvement signals.

Bacopa is studied for anti-Parkinsonian potential based on its neuroprotective profile. Animal model evidence shows protection against dopaminergic neurodegeneration, reduced α-synuclein aggregation, and nigrostriatal protection against MPTP-induced parkinsonism. No human clinical trials in Parkinson's disease patients have been published.

Preclinical animal evidence shows Boswellia serrata extract protects nigrostriatal dopaminergic neurons and improves motor impairments in a 6-OHDA rat model of Parkinson's disease. No human clinical trial has been conducted in Parkinson's patients. Traditional Ayurvedic texts also list psychological and movement-disorder applications.

Bacopa monnieri is studied for Parkinson's neuroprotection primarily in preclinical models, with evidence for reduced dopaminergic neuronal degeneration, α-synuclein aggregation inhibition, and oxidative stress reduction. Traditional use in neurological disorders and preclinical promise exist, but human clinical data are absent.